TransCode Therapeutics - שינוי בהכנסות משנה לשנה ב-12 החודשים האחרונים RNAZ

This chart of core revenue YoY dynamics over a rolling 12-month period confirms that TransCode Therapeutics (RNAZ) remains independent of market volatility due to medtech demand. The value 0.00 represents the current level of the metric. TransCode Therapeutics (RNAZ) is implementing RNA therapy against brain and breast tumors using a unique molecule delivery method. Developments in RNA cellular transport are creating valuable patent capital.

This indicator measures the volatility of revenue growth rates over a rolling twelve-month period, allowing for an assessment of the stability of incoming cash flows. Analyzing the relative year-over-year (LTM) revenue dynamics helps investors identify the risks of sharp income fluctuations, which is critical for TransCode Therapeutics (RNAZ), as the company utilizes outsourcing for drug synthesis via CMOs to minimize capital expenditures on its own laboratories.